临床外科杂志 ›› 2023, Vol. 31 ›› Issue (10): 931-935.doi: 10.3969/j.issn.1005-6483.2023.10.009

• 论著 • 上一篇    下一篇

可溶性白细胞分化抗原CD14亚型、Toll样受体4诊断急性胰腺炎并发肾损伤的临床价值

  

  1. 266000  青岛市中医医院普外三科(郝磊);青岛西海岸新区疾病预防控制中心免疫规划科(徐云玲);青岛市妇女儿童医院甲乳科(郝坤)
  • 收稿日期:2022-10-27 接受日期:2022-10-27 出版日期:2023-10-20 发布日期:2023-10-20

The clinical value of preseptin and Toll Like Receptor 4 in the diagnosis of acute pancreatitis complicated with renal injury

  1. Department of The Third General Surgery,Qingdao Traditional Chinese Medicine Hospital,Qingdao 266000,China
  • Received:2022-10-27 Accepted:2022-10-27 Online:2023-10-20 Published:2023-10-20

摘要: 目的   分析可溶性白细胞分化抗原CD14亚型(Presepsin)、Toll样受体4(TLR4)在急性胰腺炎(AP)病人中的水平及评估肾损伤发生风险的价值。  方法   2020年6月~2021年12月我院AP病人132例为AP组,同期健康体检者66例为对照组。AP组与对照组均检测血清Presepsin、TLR4水平,采用Spearman相关系数分析AP组血清Presepsin、TLR4水平与病情程度的相关性。分析AP组发生肾损伤的影响因素及Presepsin、TLR4水平对肾损伤发生风险的交互作用。采用受试者工作特征(ROC)曲线分析血清Presepsin、TLR4预测AP组发生肾损伤的价值并进行决策曲线、临床影响曲线验证。  结果   AP组血清Presepsin、TLR4水平高于对照组(P<0.05);AP组血清Presepsin、TLR4水平与病情程度均呈正相关关系(r1=0.794,P1<0.001;r2=0.835,P2<0.001);血清Presepsin、TLR4水平是AP病人发生肾损伤的影响因素(P<0.05);血清Presepsin、TLR4对AP病人发生肾损伤存在协同作用,协同效应为二者单独存在产生效应之和的1.095倍(SI=1.095);血清Presepsin>1 021.88ng/L、TLR4>31.85ng/ml时AP病人发生肾损伤风险较高,联合检测的AUC值为0.851;在阈值0.12~0.78范围内,Presepsin、TLR4联合评估AP病人发生肾损伤净受益率优于单独检测,在各阈值概率下,被联合检测方案划分为高风险的人数与真阳性例数在阈值概率为0.51时,两者基本达到一致。  结论   AP发生后血清Presepsin、TLR4水平随病情程度加重而异常升高,血清Presepsin、TLR4高水平表达是AP病人发生肾损伤的独立危险因素,且二者对肾损伤发生存在协同作用,通过联合检测其水平评估肾损伤发生风险具有较高价值。

关键词: 急性胰腺炎, 肾损伤, 可溶性白细胞分化抗原CD14亚型, Toll样受体4

Abstract: Objective   Aim To analyze the levels of soluble leukocyte differentiation antigen CD14 subtype(Presepsin) and Toll-like receptor 4(TLR4) in patients with acute pancreatitis(AP) and their value in assessing the risk of renal injury.  Methods   A total of 132 patients with AP in our hospital from June 2020 to December 2021 were selected,and 66 healthy subjects were selected during the same period.The serum Presepsin and TLR4 levels were detected in both AP patients and healthy subjects.Spearman correlation coefficient was used to analyze the correlation between serum Presepsin and TLR4 levels and disease severity in AP patients.The influencing factors of renal injury in AP patients and the interaction of Presepsin and TLR4 levels on the risk of renal injury were analyzed.Receiver operating characteristic(ROC) curve was used to analyze the value of serum Presepsin and TLR4 in predicting renal injury in AP patients,and the decision curve and clinical impact curve were used to verify.  Results   The serum Presepsin and TLR4 levels in AP patients were higher than those in healthy people(P<0.05).The serum Presepsin and TLR4 levels in AP patients were positively correlated with the severity of the disease(r1=0.794,P1<0.001;r2=0.835,P2<0.001).Serum Presepsin and TLR4 levels were the influencing factors of renal injury in AP patients(P<0.05).Serum Presepsin and TLR4 had a synergistic effect on renal injury in AP patients,and the synergistic effect was 1.095 times the sum of the effects of the two alone(SI=1.095).When serum Presepsin>1 021.88 ng/L and TLR4>31.85 ng/ml,AP patients had a higher risk of renal injury,and the AUC value of combined detection was 0.851.Within the threshold range of 0.12 to 0.78,the combined assessment of Presepsin and TLR4 for the net benefit rate of renal injury in patients with AP was superior to the independent detection.At each threshold probability,the number of people classified as high risk by the joint detection scheme and the number of true positive cases were basically consistent when the threshold probability was 0.51.  Conclusion   After the occurrence of AP,the levels of serum Presepsin and TLR4 increase abnormally with the severity of the disease.The high levels of serum Presepsin and TLR4 are independent risk factors for renal injury in AP patients,and the two have a synergistic effect on the occurrence of renal injury.Horizontal assessment of the risk of renal injury has high value and it can provide early warning in clinical practice.

Key words: acute pancreatitis, kidney injury, soluble leukocyte differentiation antigen CD14 isoform, Toll-like receptor 4

[1] 李光泽 张济 林昌俭 王垚柯 俞慎林. 高迁移率蛋白1/Toll样受体4信号通路与下肢动脉硬化闭塞症介入治疗后复发的相关性分析[J]. 临床外科杂志, 2023, 31(6): 593-596.
[2] 王梓年 李静喆 张其勇 王煊 康祺 任彦顺. 主动经皮穿刺置管引流感染性坏死组织对重症急性胰腺炎病人转归的影响[J]. 临床外科杂志, 2023, 31(5): 453-456.
[3] 李博文 韩元圣 黄高俊 郑磊. 微小RNA-370-3p和Toll样受体4在结直肠癌组织中的表达及临床意义[J]. 临床外科杂志, 2022, 30(9): 860-864.
[4] 刘丹希 孙备. 重症急性胰腺炎治疗的热点问题[J]. 临床外科杂志, 2022, 30(7): 617-620.
[5] 官艳 张国娇 罗茵. 基于机器学习算法构建重症急性胰腺炎病人肠内营养误吸风险的预测模型#br#[J]. 临床外科杂志, 2022, 30(7): 634-638.
[6] 钟蛟 刘建和 刘浩然. 肾乳头钙化斑形成过程引起的肾脏损伤[J]. 临床外科杂志, 2022, 30(3): 293-296.
[7] 张慧敏 解凤妮 吴肖 李云龙. 重症胰腺炎腹腔开放冲洗引流术后早期卧床踏步机运动对恢复的影响[J]. 临床外科杂志, 2022, 30(10): 973-976.
[8] 杨福刚 胡双 马超 徐成仕 水华 李志强. 非创伤性蛛网膜下腔出血病人住院病死相关危险因素分析[J]. 临床外科杂志, 2020, 28(9): 832-836.
[9] 唐强 黄河 覃群. 重症急性胰腺炎病人腹壁受累的多层螺旋CT及MRI研究[J]. 临床外科杂志, 2020, 28(9): 872-874.
[10] 方琦 陶京 常剑 朱孔凡 荣愈平 梅佩. 可溶性程序性死亡受体-1与重症急性胰腺炎并发持续炎症-免疫抑制-分解代谢综合征的相关性分析[J]. 临床外科杂志, 2020, 28(3): 254-257.
[11] 刘胜新:徐军辉:蔡涛等. IL-1β在急性胰腺炎时肝损伤中的作用[J]. 临床外科杂志, 2019, 27(9): 777-778.
[12] 罗文婷, 谭碧君, 甘田, 熊智魁, 周利华. 超声引导经皮腹膜后穿刺置管引流前腹腔穿刺引流治疗重症急性胰腺炎的临床价值[J]. 临床外科杂志, 2019, 27(5): 412-415.
[13] 张洋, 胡继盛, 孙备. 重症急性胰腺炎器官功能维护重要性及实施方案[J]. 临床外科杂志, 2019, 27(12): 1015-1017.
[14] 刘钢 胡如进 张丽君 马建赢. 血清淀粉酶、前白蛋白和白蛋白在氨基酸支持经内镜逆行胰胆管造影治疗急性胰腺炎前后的变化及意义   [J]. 临床外科杂志, 2018, 26(9): 693-695.
[15] 于广才, 昌盛, 陈松等. 移植肾功能恢复延迟伴发横纹肌溶解症一例[J]. 临床外科杂志, 2018, 26(12): 910-912.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 凌地洋;王哲银;卢振和;等. 自体血注射联合吲哚美辛巴布膏治疗顽固性网球肘的临床疗效观察[J]. 临床外科杂志, 2016, 24(11): 882 .
[2] 蔡贤华;齐凤宇. 髋臼骨折的治疗策略选择[J]. 临床外科杂志, 2016, 24(5): 325 -0 .
[3] 张鹏;李恒. 急性单纯性阑尾炎保守治疗与腹腔镜阑尾切除术治疗效果比较[J]. 临床外科杂志, 2017, 25(4): 277 .
[4] 王官峰;陈如 马锋. 输尿管软镜碎石术联合微创经皮肾镜取石术治疗部分鹿角状肾结的临床疗效分析[J]. 临床外科杂志, 2017, 25(4): 304 .
[5] 刘韦成;周燕;江从庆;等. 出口梗阻型便秘外科治疗进展[J]. 临床外科杂志, 2017, 25(4): 310 .
[6] 李祥;红梅;吴奇;等. 阿帕替尼在恶性肿瘤中的研究进展[J]. 临床外科杂志, 2017, 25(4): 314 .
[7] 张卉颖;陆丽;何绮月. 急性会厌炎气管切开术困难气道插管一例[J]. 临床外科杂志, 2017, 25(4): 279 .
[8] 孟旭;张海波;韩薇. 再议中国风湿性二尖瓣修复技术的临床应用[J]. 临床外科杂志, 2017, 25(5): 335 .
[9] 卢勇;翁霞惠;俞凡等. 坐浴1号对痔疮术后疼痛和水肿及创面菌落的影响研究[J]. 临床外科杂志, 2018, 26(1): 43 .
[10] 林海鹏 卢晓明 王莉霞 牛彦锋. 沉默信息调节因子7在胃癌组织的表达及其与胃癌临床病理的关系[J]. 临床外科杂志, 2018, 26(10): 744 -746 .